Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever

Wallace, David B.; Ellis, C.E.; Espach, A.; Smith, S J; Greyling, Roelf Rudolph; Viljoen, G. J.

doi:10.1016/j.vaccine.2006.06.041

Cited by 105 publications

(109 citation statements)

References 30 publications

Supporting

Mentioning

103

Contrasting

Order By: Relevance

“…Other vaccines in development for RVF include attenuated RVFV strains with deletions in the NSs gene (25), DNA, and subunit (27)(28)(29)(30). Recombinant poxvirus vaccines have been previously developed using the lumpy skin disease virus or the WR strain of VACV as vectors (31,32). However, lumpy skin disease virus vectors can only be used in areas endemic for lumpy skin disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice

Papin¹,

Verardi

Jones³

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Rift Valley fever (RVF) is a zoonotic disease endemic in Africa and the Arabian Peninsula caused by the highly infectious Rift Valley fever virus (RVFV) that can be lethal to humans and animals and results in major losses in the livestock industry. RVF is exotic to the United States; however, mosquito species native to this region can serve as biological vectors for the virus. Thus, accidental or malicious introduction of this virus could result in RVFV becoming endemic in North America. Such an event would likely lead to significant morbidity and mortality in humans, and devastating economic effects on the livestock industry. Currently, there are no licensed vaccines for RVF that are both safe and efficacious. To address this issue, we developed two recombinant RVFV vaccines using vaccinia virus (VACV) as a vector for use in livestock. The first vaccine, vCOGnGc, was attenuated by the deletion of a VACV gene encoding an IFN-γ binding protein, insertional inactivation of the thymidine kinase gene, and expression of RVFV glycoproteins, Gn and Gc. The second vaccine, vCOGnGcγ, is identical to the first and also expresses the human IFN-γ gene to enhance safety. Both vaccines are extremely safe; neither resulted in weight loss nor death in severe combined immunodeficient mice, and pock lesions were smaller in baboons compared with the controls. Furthermore, both vaccines induced protective levels of antibody titers in vaccinated mice and baboons. Mice were protected from lethal RVFV challenge. Thus, we have developed two safe and efficacious recombinant vaccines for RVF.

show abstract

Section: Discussionmentioning

confidence: 99%

“…We developed a rVACV vaccine for RVF with deletions in TK and B8R genes and expressing the two glycoproteins of RVFV (vCOGnGc) that have been shown to induce VN antibodies and protective immunity to the disease (31). A second vaccine for RVF, identical to the first vaccine except for expressing HuIFNγ (vCOGnGcγ), was also developed.…”

Section: Discussionmentioning

confidence: 99%

Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice

Papin¹,

Verardi

Jones³

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…The common immunogenic properties of these viruses have been used for the preparation of live attenuated vaccines that protect all ruminants against CaPV infection (Kitching et al, 1987). Recombinant CaPVs have also been developed for multivalent vaccination purposes (Berhe et al, 2003;Perrin et al, 2007;Romero et al, 1993;Wade-Evans et al, 1996;Wallace et al, 2006). However, although they are antigenically closely related, restriction enzyme pattern analysis, cross-hybridization studies and, more recently, nucleic acid sequencing have shown that nearly all CaPVs can be grouped according to their host origins Cao et al, 1995;Gershon & Black, 1988;Kitching et al, 1989;Tulman et al, 2002).…”

mentioning

confidence: 99%

Capripoxvirus G-protein-coupled chemokine receptor: a host-range gene suitable for virus animal origin discrimination

Goff

Lamien

Fakhfakh

et al. 2009

Journal of General Virology

143

142

View full text Add to dashboard Cite

The genus Capripoxvirus within the family Poxviridae comprises three closely related viruses, namely goat pox, sheep pox and lumpy skin disease viruses. This nomenclature is based on the animal species from which the virus was first isolated, respectively, goat, sheep and cattle. Since capripoxviruses are serologically identical, their specific identification relies exclusively on the use of molecular tools. We describe here the suitability of the G-protein-coupled chemokine receptor (GPCR) gene for use in host-range grouping of capripoxviruses. The analysis of 58 capripoxviruses showed three tight genetic clusters consisting of goat pox, sheep pox and lumpy skin disease viruses. However, a few discrepancies exist with the classical virus-host origin nomenclature: a virus isolated from sheep is grouped in the goat poxvirus clade and vice versa. Intra-group diversity was further observed for the goat pox and lumpy skin disease virus isolates. Despite the presence of nine vaccine strains, no genetic determinants of virulence were identified on the GPCR gene. For sheep poxviruses, the addition or deletion of 21 nucleic acids (7 aa) was consistently observed in the 59 terminal part of the gene. Specific signatures for each cluster were also identified. Prediction of the capripoxvirus GPCR topology, and its comparison with other known mammalian GPCRs and viral homologues, revealed not only a classical GPCR profile in the last three-quarters of the protein but also unique features such as a longer N-terminal end with a proximal hydrophobic a-helix and a shorter serine-rich C-tail.3These authors contributed equally to this work.Two supplementary tables are available with the online version of this paper.Journal of General Virology (2009), 90, 1967-1977 DOI 10.1099 Davies, 1981Davies, , 1982Diallo & Viljoen, 2007). CaPV infections lead to similar clinical signs in sheep and goats, mainly characterized by fever, excess salivation, conjunctivitis and rhinitis with ocular and nasal discharges. These symptoms are followed by eruption of pox lesions throughout the skin. LSD is a subacute to acute cattle disease with appearance of skin nodules. During epizootics of CaPVs in domestic animals, disease in wild ungulates has never been reported (Davies, 1991), although serology and isolated cases suggests that wildlife species have a possible role in virus maintenance.CaPVs are generally considered to be host-specific, leading to outbreaks in one preferred host. This is partially true since some SPPV and GTPV isolates are capable of causing severe diseases in both sheep and goats (Davies, 1976;Kitching et al., 1989). An in-depth epidemiological investigation to specifically identify the viruses involved in acute small ruminant pox diseases cannot be achieved by serological testing alone due to the very close antigenic relationship between CaPVs, with the existence of only one serotype (Kitching et al., , 1989. The common immunogenic properties of these viruses have been used for the preparation of live attenuated vaccines that ...

show abstract

“…Indeed, vaccination with N antigen has been shown to protect mice from wild-type RVFV challenge (Wallace et al 2006, Liu et al 2008, Lorenzo et al 2008, Lagerqvist et al 2009, Jansen van Vuren et al 2010, Lorenzo et al 2010. Remarkably, the glycoprotein Gne also showed an early-response reactivity (day 3 pv) in western blot and ELISA with MP12-vaccinated sera and was detected by day-28 pi sera from all ZH501-infected sheep.…”

Section: Figmentioning

confidence: 96%

Rift Valley Fever Virus Structural and Nonstructural Proteins: Recombinant Protein Expression and Immunoreactivity Against Antisera from Sheep

Faburay

Wilson²,

McVey³

et al. 2013

Vector-Borne and Zoonotic Diseases

View full text Add to dashboard Cite

The Rift Valley fever virus (RVFV) encodes the structural proteins nucleoprotein (N), aminoterminal glycoprotein (Gn), carboxyterminal glycoprotein (Gc), and L protein, 78-kD, and the nonstructural proteins NSm and NSs. Using the baculovirus system, we expressed the full-length coding sequence of N, NSs, NSm, Gc, and the ectodomain of the coding sequence of the Gn glycoprotein derived from the virulent strain of RVFV ZH548. Western blot analysis using anti-His antibodies and monoclonal antibodies against Gn and N confirmed expression of the recombinant proteins, and in vitro biochemical analysis showed that the two glycoproteins, Gn and Gc, were expressed in glycosylated form. Immunoreactivity profiles of the recombinant proteins in western blot and in indirect enzyme-linked immunosorbent assay against a panel of antisera obtained from vaccinated or wild type (RVFV)-challenged sheep confirmed the results obtained with anti-His antibodies and demonstrated the suitability of the baculo-expressed antigens for diagnostic assays. In addition, these recombinant proteins could be valuable for the development of diagnostic methods that differentiate infected from vaccinated animals (DIVA).

show abstract

Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever

Cited by 105 publications

References 30 publications

Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice

Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice

Capripoxvirus G-protein-coupled chemokine receptor: a host-range gene suitable for virus animal origin discrimination

Rift Valley Fever Virus Structural and Nonstructural Proteins: Recombinant Protein Expression and Immunoreactivity Against Antisera from Sheep

Contact Info

Product

Resources

About